Clinical trial · Interventional
Lapatinib/Carboplatin/Paclitaxel in Previously Treated Ovarian or Breast Cancer Patients
Phase I/II Lapatinib Plus Carboplatin and Paclitaxel in Stage III or IV Relapsed Ovarian or Stage IV Breast Cancer Patients
NCT00316407CI-TRIAL-00004435completedPhase 1 / Phase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is to determine the effectiveness, safety, tolerability and best dose of Lapatinib (GW572016) in combination with carboplatin and paclitaxel.
Conditions
Conditions (3)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Ovarian Epithelial Cancer Stage III | Ovarian Carcinoma | CURATED_BROADER | 0.78 |
| Stage IV Breast Cancer | Malignant Breast Neoplasm | CURATED_BROADER | 0.78 |
| Stage IV Ovarian Cancer | Malignant Ovarian Neoplasm | CURATED_BROADER | 0.78 |
Interventions
Interventions (3)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Carboplatin | Drug | Carboplatin | ALIAS |
| lapatinib (GW572016) | Drug | Lapatinib | ALIAS |
| Paclitaxel | Drug | Paclitaxel | ALIAS |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- Toxicity
- timeFrame
- 1 year
Secondary outcomes (1)
- measure
- Objective response (PR or CR)
- timeFrame
- 1 year
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Relapsed (Stage III or IV) ovarian, primary peritoneal, fallopian tube carcinoma patients. * Stage IV metastatic breast cancer patients who have failed no more than four previous chemotherapies for Stage IV disease. * Ability to swallow and retain oral medications. * Measurable disease Exclusion Criteria: * Treatment with previous weekly carboplatin and paclitaxel. * No prior treatment with erbB targeting therapies such as erlotinib, gefitinib and cetuximab. * No concomitant requirement for medication classification as CYP3A4 inducers or inhibitors.
References
Publications (0)
Data not yet available
No reference posted for this study.